Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2025 16:34 ET | Source: Climb Bio, Inc.

Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases,...
May 19, 2025 16:15 ET | Source: CRISPR Therapeutics AG

CRISPR Therapeutics and Sirius Therapeutics Announce Multi-Target Collaboration to Develop Novel siRNA Therapies

-Collaboration brings together complementary capabilities to co-develop and co-commercialize SRSD107, a next generation, long-acting Factor XI (FXI) small interfering RNA (siRNA) for the treatment of...
May 19, 2025 16:05 ET | Source: Annexon Biosciences

Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting

First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care...
May 19, 2025 14:41 ET | Source: Sutter Health

Sutter Health Awarded Proposition 1 Funding to Expand Behavioral Health Services Across Northern California

Northern California, May 19, 2025 (GLOBE NEWSWIRE) -- Building upon its commitment to expanding access to timely, high-quality mental health care, not-for-profit Sutter Health today announced it has...
May 19, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Lysosomal Storage Disorders Market Set to Expand Across the 7MM During the Forecast Period (2025–2034) with Advances in Enzyme Replacement Therapies | DelveInsight

New York, USA, May 19, 2025 (GLOBE NEWSWIRE) -- Lysosomal Storage Disorders Market Set to Expand Across the 7MM During the Forecast Period (2025–2034) with Advances in Enzyme Replacement Therapies |...
May 19, 2025 12:15 ET | Source: Boehringer Ingelheim Limited

Global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF and PPF, with similar discontinuation rates to placebo

Nerandomilast, an investigational agent, met the primary endpoint of both phase III trials, FIBRONEER™-IPF and FIBRONEER™-ILD, significantly reducing the decline in forced vital capacity (FVC) [mL] by...
May 19, 2025 12:06 ET | Source: Foundation for Sarcoidosis Research

The Coalition to Transform Clinical Trial Engagement Launches National “Champions for Change – PTO Initiative” to Expand Access to Clinical Trials for Working Patients with 7 Corporate and Non-Profit Members

Coalition to Transform Clinical Trial Engagement (CTCTE) announces launch of Champions for Change – Paid Time Off (PTO) Initiative.
May 19, 2025 11:48 ET | Source: NovelMed Therapeutics Inc

NovelMed’s Phase II Data in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Shows Best-in-Class Efficacy as Monotherapy

--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare...
May 19, 2025 11:30 ET | Source: PhotoniCare

PhotoniCare's OtoSight Demonstrates More Accurate Diagnosis and a 50 Percent Reduction in Antibiotic Usage for Pediatric Ear Infections in Large Randomized Controlled Trial

DURHAM, N.C. and GRAND RAPIDS, Mich., May 19, 2025 (GLOBE NEWSWIRE) -- PhotoniCare Inc., a medical device company dedicated to delivering innovation to frontline care that demonstrably enhances...
May 19, 2025 11:29 ET | Source: ImpactLife

Emergency Response and the Blood Supply

Davenport, Iowa, May 19, 2025 (GLOBE NEWSWIRE) -- This week, ImpactLife joins emergency medical services providers across our region in celebrating May 18-24 as Emergency Medical Services Week. The...